Click Therapeutics & Boehringer Ingelheim Secure Series D Funding To Advance Commercialization Of CT-155 Digital Therapeutic For Schizophrenia

Boehringer Ingelheim and Click Therapeutics have reached an agreement under which Click Therapeutics will assume full commercial and regulatory responsibility for CT-155, an investigational prescription digital therapeutic being studied as a treatment for negative symptoms of schizophrenia in adults. Boehringer has made a $50 million Series D investment in Click Therapeutics and has provided additional commercial funding to support the potential launch of CT-155, pending clearance from the U.S. Food and Drug Administration (FDA). The two companies previously co-developed the product together.

CT-155 is a software-based intervention designed to deliver psychosocial techniques as a . . .